Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients

Noce A, Albanese M, Marrone G, Di Lauro M, Pietroboni Zaitseva A, Palazzetti D, Guerriero C, Paolino A, Pizzenti G, Di Daniele F, Romani A, D'Agostini C, Magrini A, Mercuri NB, Di Daniele N. Pharmaceuticals, 2021; 14(4):336.

ReviewHumansOther animals

Design

Review

What was measured

A literature review setting out the case for ultramicronised palmitoylethanolamide as an add-on in COVID-19

What the authors reported

The authors propose, from earlier laboratory and clinical work, that its effects on immune response and inflammation could limit organ damage in COVID-19. They note that pharmacokinetic data are limited. The article reports no patient data.

Limits of this study

A hypothesis paper with no new data. The same group later ran a small study in patients: see Albanese 2022. For a placebo-controlled trial, see Fessler 2022, which found a difference in one of six main blood markers. Funding and conflict statements were not visible on the page checked.

Source

doi:10.3390/ph14040336

Entry checked against the full text at the publisher (MDPI) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.